

Anti-CSF2/GM-CSF Antibody (Gimsilumab)

Introduction

Gimsilumab is a humanized anti-GM-CSF monoclonal antibody. Gimsilumab has the potential to be studied in COVID-19 and rheumatoid arthritis.

Product parameters

Alternative Names	MORAb-022
Target Accession	P04141
Target	CSF2 / GM-CSF
CAS number	1648796-29-5
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Anti-CSF2/GM-CSF Antibody (Gimsilumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

